Complete remission rate of 69% in blastic plasmacytoid dendritic cell neoplasm
— Complete remission rate of 69% in blastic plasmacytoid dendritic cell neoplasm
May 27, 2026
• 2 min read
The FDA approved the antibody-drug conjugate pivekimab sunirine (Decnupaz) for the rare hematologic malignancy blastic plasmacytoid dendritic cell neoplasm (BPDCN).
The approval stipulates use of the drug in adults. Although BPDCN occurs most often in patients ages 60 and older, the condition can affect patients in any age group.
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
FDA clears Gilead's hepatitis D drug, four years after prior rejection
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
Leucemia linfatica cronica, ok da Aifa a rimborsabilità in Italia di pirtobrutinib
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell…
Datopotamab deruxtecan indicated for patients ineligible for immunotherapy
The FDA approved datopotamab deruxtecan-dlnk as the first TROP2-directed antibody drug conjugate for first-line treatment of…
The U.S. Food and Drug Administration announced the approval of the first hematopoietic stem cell transplant therapy to treat…
All-oral combination indicated for patients ineligible for intensive chemotherapy
AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory…
